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Retrospective Study of Adverse Events of Chemotherapy in Cats
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ABSTRACT
Background: Clients who seek veterinary care for pets with cancer are often concerned about the potential negative im-
pact of chemotherapeutic treatments on their animals’ quality of life. A consensus currently exists in veterinary oncology 
regarding the quantification and rating of adverse treatment effects in dogs and cats in response to chemotherapy agents. 
This grading system is referred to as Veterinary Cooperative Oncology Group - Common Terminology Criteria for Adverse 
Events. The purpose of this retrospective case series was to investigate the delayed acute effects of chemotherapy drugs 
in cats receiving cancer treatment.
Materials, Methods & Results: Medical records were reviewed to determine the chemotherapy agent used and delayed adverse 
effects. Side effects were classified according to Veterinary Co-operative Oncology Group grading. All cats were evaluated 
after the first chemotherapy administration, after a single dose. The reported effects included hematologic effects (e.g., 
neutropenia, thrombocytopenia, increases in liver enzymes, and azotemia), gastrointestinal effects (e.g., vomiting, diarrhea, 
and inappetence), and sepsis. All of the cats in this study received ondansetron and omeprazol  in the first five days following 
chemotherapy administration. If vomiting occurred with oral medication, maropitant was administered subcutaneously 
for three consecutive days. If diarrhea (> grade II) occurred, probiotics were administered for seven days. Hematologic 
examination was performed 3-14 days after chemotherapy. If neutropenia (> grade III) occurred, Human granulocyte colony 
stimulating factor was administered subcutaneously for three consecutive days together with prophylactic antibiotics. 
Lomustine, carboplatin, vincristine, doxorubicin, cyclophosphamide, mitoxantrone, and vinblastine were administered 
in 33%, 19%, 16%, 5%, 16%, 10% and 2% of the cases examined, respectively. The most common adverse events were 
vomiting, inappetence, neutropenia, and thrombocytopenia. Vomiting occurred in 6% cases, most of them associated with 
cyclophosphamide. Inappetence/anorexia affected 12% of the cases, mostly those involving cyclophosphamide or doxorubicin. 
Neutropenia was observed in 22% of the cases, with cyclophosphamide, followed by carboplatin and lomustine. According 
to the current grading system of adverse effects induced by chemotherapy, grade I toxicity was observed in 83% of the cases, 
whiles grade II-IV were observed in 7%, 8%, and 2% of the cases examined, respectively.
Discussion: In general, the chemotherapy regimens in the cases examined were well tolerated. The toxicity experienced 
was infrequent and mostly mild, thereby resulting in satisfactory tolerability of the chemotherapy regimens. According to 
the current grading system for the adverse effects of chemotherapy, 83% of the cases examined included grade I, indicating 
that most of the cats experienced asymptomatic, or mild symptoms, and medical intervention was not needed. In previous 
studies of dogs and cats, a severe adverse event following chemotherapy was reported for fewer than 1 in 4 animals, 
and approximately 3-5% experienced a serious adverse event that led to hospitalization. In the present study, 2% of the 
cats experienced serious or life threatening adverse events. The only chemotherapeutic agent that was associated with 
inappetence, vomiting, and neutropenia was cyclophosphamide. Based on the data examined, we would recommend that 
cyclophosphamide should be used with caution for the treatment of cancer in cats, with adequate antiemetic and nutritional 
support available if needed. In addition, febrile neutropenia/sepsis may be avoided by using a fractionated schedule.
Keywords:  feline, oncology, chemotherapy, side effects, tolerability.
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INTRODUCTION
Clients who seek veterinary care for pets with 
cancer are often concerned about the potential nega-
tive impact of chemotherapeutic treatments on their 
animals’ quality of life [14,16]. The toxicity profiles 
associated with anticancer agents have included im-
mediately evident toxicities (e.g., those that develop 
within 24-48 h after treatment), acute delayed effects 
(e.g., those that develop within 2-14 days after tre-
atment), and/or cumulative/chronic toxicity (effects 
extending over weeks, months, or years). Delayed acute 
effects from chemotherapy often include bone marrow 
suppression and nausea, vomiting, and diarrhea. In the 
majority of instances, these effects are self-limiting 
and the incidence of hospitalization for such proble-
ms is low [4]. Examples of potential cumulative and/
or chronic toxicity include hepatic dysfunction after 
multiple doses of cyclohexylchloroethylnitrosourea 
(CCNU, also known as lomustine), cardiac abnorma-
lities after exceeding a usually safe cumulative dose 
of doxorubicin, and renal disease after administration 
of doxorubicin in cats [4].
A consensus currently exists in veterinary 
oncology regarding the quantification and rating of 
adverse treatment effects in dogs and cats in response to 
chemotherapy agents. This grading system is referred 
to as Veterinary Cooperative Oncology Group - Com-
mon Terminology Criteria for Adverse Events (VCOG-
-CTCAE) [15]. The purpose of this retrospective case 
series was to investigate the delayed acute effects of 
chemotherapy drugs in cats receiving cancer treatment.
MATERIALS AND METHODS
Medical records
This retrospective study involved 112 cats 
treated with chemotherapy between August 2011 and 
August 2016 at Oncopet Veterinary Clinic (Rio de 
Janeiro, Brazil). All of the cats were previously diag-
nosed with malignant neoplasia and chemotherapy was 
prescribed as a definitive and/or adjuvant treatment.
Medical records were reviewed to  determine 
the chemotherapy agents used and the delayed 
acute toxicity effects observed between 12 h and 
21 d after the administration of chemotherapy. 
The chemotherapy agents administered included 
vincristine, vinblastine, lomustine, cyclophospha-
mide, doxorubicin, mitoxantrone, and carboplatin, 
according to neoplasm histologic type, treatment 
protocol, comorbidities. All cats were evaluated after 
the first chemotherapy administration, after a single 
dose.  For example, vincristine was evaluated in cats 
receiving OP protocol, after first time the cat received 
this chemotherapy. However, cyclophosphamide was 
evaluated in cats receiving COP protocol, and it was 
started as a 4-day cycle after 2 days of vincristine. The 
reported effects included hematologic effects (e.g., 
neutropenia, thrombocytopenia, increases in liver 
enzymes, and azotemia), gastrointestinal effects 
(e.g., vomiting, diarrhea, and inappetence), and 
sepsis. A summary of the adverse events grading is 
provided in Table 1. Late, cumulative, and/or chronic 
toxicity (e.g., hepatic dysfunction, cardiac abnormali-
ties, and chronic renal disease) were not studied, due 
to the fact that this retrospective study involved only 
the follow-up of cats after a chemotherapy single dose, 
and for a short period of time.
The following factors were statistically exami-
ned to determine their relationship to the chemotherapy 
agents used and their impact on the owners’ opinions 
about treatment: age (< 7 y, 8-11 y, or > 12 y), breed 
(divided into mixed breed, Siamese, Maine Coon, Rag-
doll, and Persian), neoplasm histologic type (lymphoma, 
carcinoma, mast cell tumor, melanoma, sarcoma, thy-
moma), and presence of concomitant disease (retroviral, 
endocrine, cardiovascular, renal, gastrointestinal).
Side effects classification
Side effects were classified according to 
VCOG-CTCAE grading of adverse effect severity [15] 
as follows: grade I (asymptomatic, or mild symptoms; 
clinical signs or diagnostic observations only; inter-
vention not indicated); grade II (moderate; minimal, 
outpatient, or noninvasive intervention indicated; mo-
derate limitation of daily living activities); grade III 
(severe or medically significant but not immediately 
life-threatening; hospitalization or prolongation of 
hospitalization indicated; disabling; significantly limi-
ted daily living activities); grade IV (life-threatening 
consequences; urgent interventions indicated), and 
grade V (death related to adverse events).
All of the cats in this study received prophylactic 
and supportive treatment according to the same protocol. 
Animals receiving chemotherapy received ondansetron 
(Vonau®)1 administered at a dose of 0.5 mg kg-1 orally, 
BID, and omeprazol (Gaviz®)2 at a dose of 1 mg kg-1 
orally, SID, in the first five days following chemotherapy 
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administration, independent of the chemotherapy 
drug administered. If vomiting occurred with oral 
medication, maropitant (cerenia®)3 at a dose of 2 mg 
kg -1 was administered subcutaneously, SID, for three 
consecutive days, as oral medication was maintained. In 
addition, the animals were fed a special diet in case of 
vomiting/anorexia (Hill´s Prescription a/d®)4 or (Royal 
Canin Gastrointestinal®)5. When necessary, feeding was 
forced, and in some cases, an e-tube was recommended. 
If diarrhea (> grade II) occurred, probiotics were 
administered for seven days. Hematologic examination 
was performed 3-14 days after chemotherapy. If 
neutropenia (> grade III) occurred, Human granulocyte 
colony stimulating factor (Filgrastim®)6 at a dose of 
5 ug kg-1 was administered subcutaneously for three 
consecutive days together with prophylactic antibiotics.
Statistical analysis
A database exploratory analysis was performed 
and comparisons between variables were made with 
the Pearson Chi-square, Kruskal-Wallis, and Mann-
-Whitney tests as appropriate. Descriptive statistics 
served as a basis for interpretation of the results. The 
level of statistical significance was 5%. Tests and 
studies were performed with the software, Statistical 
Package for the Social Sciences (SPSS; version 20.0, 
SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 112 oncologic records of various 
feline breeds were reviewed. The breeds included: mi-
xed (n = 93), Siamese (n = 13), Persian (n = 2), Maine 
Coon (n = 2), and Ragdoll (n = 2). Forty-three animals 
(38%) were older than 12 years, while 42 (38%) ranged 
from 1-7 years in age and 27 (24%) were 8-12 years 
of age. There was no statistically significant difference 
between age and adverse events of chemotherapy in 
the present study.
The neoplasm histological types were highly 
variable and were categorized as: carcinoma [mam-
mary (13/112), cutaneous squamous cell (3/112), 
cutaneous basal cell (1/112), bladder transitional cell 
(1/112), and hepatocellular (1/112)], sarcoma [soft 
tissue (11/112), chondrosarcoma (2/112), and heman-
giosarcoma (1/112)], lymphoma (68/112), visceral 
mast cell tumor (5/112), melanoma (3/112), thymoma 
(2/112), and heart base tumor (1/112). Chemotherapy 
was recommended as a definitive treatment in 39% 
cats and adjuvant treatment in 61% of the examined 
cases. Comorbidities were present in 55 (49%) animals, 
and these included renal disease (14/55) and retroviral 
diseases (feline immunodeficiency virus (FIV) and 
feline leukemia virus (FeLV) [41/55].
Various chemotherapy agents were administe-
red. The most prevalently used was lomustine, which 
was applied in 37 (33%) cases. The other agents that 
were administered included carboplatin in 21 (19%) 
cases, vincristine in 18 (16%) cases, doxorubicin in 
five (5%) cases, cyclophosphamide in 18 (16%) cases, 
mitoxantrone in 11 (10%) cases, and vinblastine in 
two (2%) cases. The doses were 50 mg/m2 orally for 
lomustine, 180 mg/m2 intravenously for carboplatin, 
0.75 mg/m2 intravenously for vincristine, 2 mg/m2 
intravenously for vinblastine, 1 mg/kg intravenously 
for doxorubicin, and 5.5 mg/m2 intravenously for 
mitoxantrone. Cyclophosphamide was administered 
orally at a dose of 200 mg/m2 that was divided into 
four daily doses (50 mg/m2 each). These doses are 
consistent with those previously published, although 
author’s preference determined the dose.
Blood exams, including hematologic exami-
nation and biochemistry [blood urea nitrogen (BUN), 
creatinine, alanine aminotransferase (ALT), and alka-
line phosphatase (ALP)], were performed for each 
animal 7-21 days after chemotherapy administration. 
For example, the animals that received lomustine 
(CCNU) underwent their exams on day 7 and day 21. 
For the animals that received carboplatin, blood exams 
were performed between days 10-14. For the animals 
that received vincristine, vinblastine, mitoxantrone, or 
doxorubicin, their exams were performed between days 
7-10. For the animals that received cyclophosphamide, 
their exams were performed on the third day of the 
4-day cycle due to the development of severe neu-
tropenia in previous cases (author experience) [Table 
2]. If neutropenia (< 1,500 neutrophils) was present, 
the 4th dose of cyclophosphamide was not given, and 
supportive treatment was administered instead. 
Severity grade I vomiting (despite prophylactic 
oral administration of antiemetics) was observed in 7 
(6%) cases. Six of these cases occurred in association 
with cyclophosphamide, and the other case occurred in 
association with vincristine. Diarrhea was not reported 
for any of the cases examined.
Various grades of inappetence/anorexia 
occurred in 17 (12%) cases. Four cases were grade 
II, 12 cases were grade III, and 1 case was grade 
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IV. Cyclophosphamide caused various grades of 
inappetence in 12/18 cats, including grade II (n = 1), 
grade III (n = 10), and grade IV (n = 1). Doxorubicin 
also caused grade II and grade III inappetence for 3 
cats and 2 cats, respectively (Figure 1).   
Neutropenia is a major side effect of 
chemotherapy and it was only observed in 25/112 
(22%) cases. The severity of neutropenia included grade 
I (2/25 cases), grade II (5/25 cases), grade III (14/25 
cases), and grade IV (4/25 cases). Cyclophosphamide 
was the chemotherapy agent responsible for most 
of the cases of neutropenia (14/18), and grades 1-4 
had an incidence of 1 case, 2 cases, 7 cases, and 4 
cases, respectively (Table 3). Carboplatin also caused 
neutropenia in 5/21 cats (including one case of grade I 
and 14 cases of grade III), as did lomustine in 5/37 cats 
(including 2 cases of grade II and 3 cases of grade III). 
Vincristine caused grade I neutropenia in 1 case, while 
doxorubicin, mitoxantrone, and vinblastine were not 
associated with any cases of neutropenia (Figure 2). 
Sepsis secondary to chemotherapy also did not occur 
in any of the animals in this study.
Thrombocytopenia was observed in 8 (7%) 
cases, with grades 1-3 affecting 3, 4, and 1 cats, 
respectively. Moreover, 4 cases were associated with 
cyclophosphamide, 3 cases were associated with 
lomustine, and 1 case involved vincristine (Figure 3). 
Table 2. Hematological examination of cats submitted to different 
chemotherapeutic drugs.
Chemotherapy agent Exams 
Lomustine Days 7 and 21
Carboplatin Days 10-14
Vincristine Days 7-10
Vinblastine Days 7-10
Mitoxantrone Days 7-10
Cyclophosphamide Day 3 (in the 4-day cycle)
Figure 1. Incidence of inappetence according to the chemotherapy agent administered.
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Azotemia (grade III) only occurred in 1 cat 
following administration of doxorubicin, and this 
cat did not have a history of renal disease. Elevated 
levels of ALT and/or ALP (grade II) were also only 
observed in 1 cat after cyclophosphamide treatment.
According to the current VCOG-CTCAE 
grading system, the adverse effects of chemotherapy 
were grade I in 93 (83%) cases, and was grades 2-4 
in 8 (7%), 9 (8%), and 2 (2%) of the other cases, 
respectively. Grade V adverse effects were not 
reported for any of the cases examined. The severity 
grades for the cases involving carboplatin treatment 
varied from 1-4, and affected 76%, 9%, 10%, and 5% 
of the cats, respectively. The severity grades for the 
cases involving cyclophosphamide treatment varied 
from 1-3, and affected 83%, 6%, and 11% of the 
cats, respectively. The severity grades for the cases 
involving lomustine treatment varied from grades 
1-4, and affected 81%, 11%, 5%, and 3% of the 
cats, respectively. The severity grades for the cases 
involving vincristine treatment varied from grades 
1-3, and affected 89%, 5.5%, and 5.5% of the cats, 
respectively. Finally, mitoxantrone treatment was 
associated with severity grades 1 and 2 in 91% and 
9% of the cases, respectively (Figure 4).
A statistical association between neutropenia, 
vomiting, inappetence, azotemia and chemotherapeutic 
agent was identified for the chemotherapy agents. 
For example, the Kruskall-Wallis test confirmed 
the presence of a statistically significant difference 
between the chemotherapy agents and the incidences 
of neutropenia, vomiting, inappetence, azotemia (P 
< 0.05). To further identify these differences, the 
Mann-Whitney statistical test was applied. In paired 
comparisons, a statistical difference was observed 
with the administration of cyclophosphamide versus 
administration of the other chemotherapeutic agents. 
For example, cyclophosphamide was associated with 
more adverse events than carboplatin, leading to 
statistically significant neutropenia (P < 0.001) and 
Figure 2. Incidence of neutropenia according to the chemotherapy agent administered.
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inappetence (P < 0.001). Cyclophosphamide also 
caused more neutropenia than doxorubicin (P = 0.007).
Doxorubicin was statistically associated with 
more inappetence when compared to lomustine (P = 
0.01) and vincristine (P = 0.03). It was not possible 
to evaluate statistical associations between the use of 
vinblastine and the other chemotherapeutic agents due 
to the smaller number of animals that were treated with 
vinblastine. Furthermore, all of the other associations 
between the chemotherapeutic agents did not exhibit 
statistically significant differences in relation to the 
variables analyzed (P > 0.05).
Cyclophosphamide was associated with 
more adverse events when compared with the other 
chemotherapeutic agents in regard to neutropenia, 
inappetence and vomiting. In contrast, cats treated 
with mitoxantrone and vinblastine were associated 
with greater tolerance.
DISCUSSION 
In general, the chemotherapy regimens in 
the cases examined were well tolerated. The toxicity 
experienced was infrequent and mostly mild, thereby 
resulting in satisfactory tolerability of the chemotherapy 
regimens. According to the current grading system for the 
adverse effects of chemotherapy (VCOG-CTCAE) [15], 
83% of the cases examined included grade I, indicating 
that most of the cats experienced asymptomatic, or mild 
symptoms, and medical intervention was not needed. In 
previous studies of dogs and cats, a severe adverse event 
following chemotherapy was reported for fewer than 1 
in 4 animals, and approximately 3-5% experienced a 
serious adverse event that led to hospitalization [1,2]. 
In the present study, 2% of the cats experienced serious 
or life threatening adverse events.
The only chemotherapeutic agent that was 
associated with inappetence, vomiting, and neutropenia 
was cyclophosphamide, a nitrogen mustard agent that is 
Figure 3. Incidence of thrombocytopenia according to the chemotherapy agent administered.
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commonly included in multiagent protocols for lymphoma 
in both dogs and cats [4]. A fractionated dosing schedule 
has been indicated in some protocols (e.g., 50 mg/m2 for 
3-4 consecutive days after doxorubicin or vincristine), 
and a similar fractionated dosing schedule was used 
for cyclophosphamide in the cases examined for this 
study. However, despite the preventive administration 
of an antiemetic, inappetence and nausea were observed 
in most of the cats that received cyclophosphamide. 
Vomiting was reported for 7 cats, and 6 of these cats 
had received cyclophosphamide. In the present study, 
inappetence occurred in 70% of the cats that received 
cyclophosphamide, and most of the conditions were 
severe or medically important, with supportive treatment 
needed.  In another study of cats, side effects were 
reported for vincristine (38%) and doxorubicin (21%) 
more often than for cyclophosphamide (15%) [12]. It is 
possible that administration route may account for these 
differences in results. Additionally, cyclophosphamide 
was evaluated in cats receiving COP protocol, which had 
received vincristine 2 days before. This fact may have 
worsened hematological and gastrointestinal effects, 
as toxicity from vincristine was also associated with 
cyclophosphamide administration.
Doxorubicin is another chemotherapeutic 
agent that has been associated with gastrointestinal 
toxicity. In particular, vomiting and anorexia are the 
most commonly reported side effects of doxorubicin 
[11]. In the present study, all the 5 cats developed 
inappetence after receiving doxorubicin.
Mitoxantrone is another chemotherapeutic agent 
that has been associated with gastrointestinal side effects 
[3,10], although none of the cats of the present cohort that 
received mitoxantrone developed vomiting, anorexia, 
or diarrhea. Similarly, carboplatin has been associated 
with gastrointestinal side effects such as lethargy, loss 
of appetite, vomiting, and diarrhea [1], yet none of the 
studied cats developed any of these side effects. 
Figure 4. Grading system of adverse events to chemotherapy according to Veterinary Cooperative Oncology Group (VCOG) criteria. 
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For the cats that experienced inappetence, 
vomiting, and/or nausea, maropitant was administered 
subcutaneously together with oral administrations of 
ondansetron and omeprazol. These drugs provided a 
good antiemetic effect, as previously reported [5]. In 
the study by Leo et al. [8], a decrease in appetite and 
vomiting represented transitory episodes during the 
first 4 weeks of treatment, and these were controlled 
with antiemetic drugs [8]. 
Administration of carboplatin and vincristine 
led to neutropenia in a subset of the cats examined, whi-
le the administration of doxorubicin, mitoxantrone, or 
vinblastine was not associated with neutropenia in any 
of the examined cases. Administration of doxorubicin 
has been shown to cause neutropenia (grades 1-4) in 
cats, and neutropenia has been more often associated 
with higher doses of doxorubicin [11]. A dose of 1 mg/
kg was used in the cases examined, and this dose has 
been associated with a reduced incidence of neutropenia 
compared with a dose of 25 mg/m2 [11]. Differences in 
the administered doses of doxorubicin may explain the 
absence of neutropenia in the cases examined. 
The administration of vinblastine was not asso-
ciated with neutropenia in the present cohort, although 
the administration of vinblastine and vincristine were 
previously associated with neutropenia in cats [6]. 
Furthermore, neutropenia has been associated with 
vinblastine more often than vincristine [6]. This ob-
servation was not made in the present study, although 
the doses applied for the 2 drugs were higher than 
previously described [6]. It is possible that the use of 
different protocols to treat cats with cancer may be a 
contributing factor to this result. 
According to Vail [14], neutropenia is likely to 
be observed 7-10 days after the administration of most 
chemotherapy drugs. Exceptions to this rule include 
vinblastine and paclitaxel, which can cause neutropenia 
as early as 4-5 days after the administration; and carbo-
platin which can occasionally cause neutropenia as late 
as 2-3 weeks after administration [4]. However, in the 
present study, 22% of the cats that received cyclophos-
phamide developed severe cases of neutropenia by the 
third day of the fractionated dosing schedule that was 
designed to extend over 4 consecutive days (50 mg/m2). 
This result differed from that reported by Leo et al. [8] 
where oral treatment with cyclophosphamide did not 
result in neutropenia. Moreover, the dose used in the 
cases examined (200 mg/m2) was higher than the dose 
used by Leo et al. [8] (metronomic 66 mg/m2 weekly). 
Thus, it appears that the incidence of neutropenia may 
be dependent on the dose of the chemotherapeutic agent 
that is applied. Additionally, the high number of cats with 
neutropenia following cyclophosphamide administration 
in the present study may be associated with the retroviral 
status. All cats treated with this chemotherapeutic agent 
had lymphoma, and 13/18 of them had FeLV and/or FIV, 
which may have worsened myelosuppression.
Most companion animals have a low risk of 
infection if their neutrophil count remains greater than 
1000/ L. However, the severity of neutropenia and 
associated sepsis can be extremely variable, ranging 
from clinically silent to overwhelming and fatal [14]. 
Sepsis did not occur in any of the cats of the present 
cohort, yet it could have developed if hematology was 
not performed on the 3rd day of each chemotherapy 
regimen. The present results also demonstrate that 
cats (especially those with retroviral diseases) appear 
to be particularly susceptible to cyclophosphamide-
-associated toxicities. Thus, cyclophosphamide should 
be used with caution for the treatment of cancer in cats, 
and the development of inappetence, vomiting, and 
neutropenia should be closely monitored.
Azotemia (grade III) occurred in only one cat 
following administration of doxorubicin, and this cat 
did not have a history of renal disease. Generally, do-
xorubicin chemotherapy is avoided in cats that have a 
history of renal disease due to the known nephrotoxic 
properties of doxorubicin [11], and mitoxantrone is 
often administered instead. In the present study, the 
administration of mitoxantrone in cats with evidence 
of renal disease may explain the low incidence of 
azotemia. Renal damage was still a possible side effect 
following mitoxantrone, as in another study, some cats 
developed azotemia with this drug [3]. In previous lite-
rature, renal toxicity has also been reported to occur in 
cats following the administration of cyclophosphamide 
[8]. However, renal damage was not reported in the 
cases examined involving cyclophosphamide in the 
present study. 
Lomustine has been shown to cause severe 
hepatotoxicity in dogs [7]. Moreover, lomustine-
induced liver injury or hepatoxicity is often suspected 
when increased activities of ALT and ALP are detected 
days to weeks after the administration of lomustine. In 
a study by Musser et al. [9], only 2/29 cats exhibited 
increased ALT activity above the reference interval 
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one month after their treatment with lomustine. 
Correspondingly, clinically significant hepatic injury 
has been found to be generally uncommon in cats that 
receive lomustine [9]. In the present study, increased 
ALT activity was not detected in any of the cats that 
received lomustine up to 21 days after their treatments.
In a previous study of owners’ perceptions 
about chemotherapy in dogs and cats, 62/69 owners 
thought that the anticancer chemotherapy regimens 
received were generally worthwhile, although only 10 
cats were included in this study. Furthermore, the most 
common side effects were hair loss, weight loss, and 
weakness, all of which affected 5/10 of the cats [2]. 
Among these effects, weight loss was the most severe.
This result may encourage veterinarians to 
administer chemotherapy to feline patients, with the 
exception being cyclophosphamide chemotherapy 
which was associated to more adverse events. In 
a previous study of owners’ perceptions of their 
cats’ quality of life during the administration of 
cyclophosphamide, vincristine sulfate, and prednisone 
(COP chemotherapy) for lymphoma, adverse effects 
were experienced by 27/31 (87%) cats [13].
CONCLUSION
For the cases examined, the chemotherapy 
regimens administered were very well tolerated. 
The most common adverse events were neutropenia, 
inappetence, thrombocytopenia and vomiting. The 
present results also indicate that cyclophosphamide 
should be used with caution in cats, especially those 
with retroviral diseases, and that adequate antiemetic 
and nutritional support should be available if needed. 
In addition, febrile neutropenia/sepsis may be avoided 
by using a fractionated schedule and performing 
hematologic exams on the third day of treatment. If 
neutropenia does develop, interruption of treatment 
and administration of supportive treatment should 
be provided. Vincristine was associated with mild 
toxicities, and carboplatin, mitoxantrone, lomustine, 
and vinblastine were very well tolerated. Thus, the 
present results demonstrate that chemotherapy can be 
well tolerated by cats and it represents a safe treatment 
for cancer when it is properly monitored.
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